Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kiniksa Pharmaceuticals, Ltd. (KNSA)

15.7481   0.018 (0.12%) 12-06 09:50
Open: 15.65 Pre. Close: 15.73
High: 15.7481 Low: 15.53
Volume: 10,670 Market Cap: 544(M)

Technical analysis

as of: 2022-12-06 9:20:00 AM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 20.08     One year: 23.45
Support: Support1: 13.58    Support2: 11.35
Resistance: Resistance1: 17.19    Resistance2: 20.08
Pivot: 16.02
Moving Average: MA(5): 16.47     MA(20): 15.77
MA(100): 12.71     MA(250): 11.24
MACD: MACD(12,26): 0.7     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 68     %D(3): 81.8
RSI: RSI(14): 55.5
52-week: High: 17.19  Low: 7.36
Average Vol(K): 3-Month: 359 (K)  10-Days: 271 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ KNSA ] has closed above bottom band by 33.2%. Bollinger Bands are 41.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.91 - 17 17 - 17.08
Low: 15.39 - 15.5 15.5 - 15.59
Close: 15.56 - 15.73 15.73 - 15.87

Company Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Headline News

Fri, 02 Dec 2022
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Down 4.5% Following Insider Selling - MarketBeat

Thu, 01 Dec 2022
Barry D. Quart Sells 21959 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock - MarketBeat

Wed, 23 Nov 2022
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference - Marketscreener.com

Mon, 21 Nov 2022
Will Kiniksa Pharmaceuticals Ltd (KNSA) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Mon, 14 Nov 2022
Should Biotechnology Stock Kiniksa Pharmaceuticals Ltd (KNSA) Be in Your Portfolio Monday? - InvestorsObserver

Thu, 10 Nov 2022
Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 35 (M)
Shares Float 27 (M)
% Held by Insiders 1.9 (%)
% Held by Institutions 45.3 (%)
Shares Short 2,730 (K)
Shares Short P.Month 2,880 (K)

Stock Financials

EPS 2.03
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.51
Profit Margin (%) 80.5
Operating Margin (%) -18.3
Return on Assets (ttm) -5.7
Return on Equity (ttm) 47.6
Qtrly Rev. Growth 719.5
Gross Profit (p.s.) 0.82
Sales Per Share 5.12
EBITDA (p.s.) -0.87
Qtrly Earnings Growth 0
Operating Cash Flow -2 (M)
Levered Free Cash Flow 5 (M)

Stock Valuations

PE Ratio 7.71
PEG Ratio -0.1
Price to Book value 2.84
Price to Sales 3.06
Price to Cash Flow -362.11

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.